B-Cell and T-Cell Combined Disorders Workup

  • Author: Terry W Chin, MD, PhD; Chief Editor: Harumi Jyonouchi, MD  more...
Updated: Aug 26, 2014

Laboratory Studies

Laboratory findings in the measurement of immune function are heterogeneous in patients with ataxia-telangiectasia (AT). Findings widely vary.

Decreased or absent levels of serum immunoglobulin A (IgA), immunoglobulin G (IgG)2, and immunoglobulin E (IgE) are the most common antibody abnormalities reported. In a review of 100 patients with AT, immunoglobulin deficiencies were common, affecting IgG4 in 65%, IgA in 63%, IgG2 in 48%, IgE in 23%, and IgG in 18%. All patients with AT produced IgG antibody to tetanus toxoid, whereas 76% did not respond to any of the pneumococcal polysaccharide serotypes. On the contrary, patients with AT do have increased pneumococcal antibody titers (levels lower than those of control subjects) after conjugated pneumococcal vaccination, although the vaccination may need to be repeated.[11]

Researchers recently observed hypergammaglobulinemia in 39% of 90 patients with AT. An isolated increase in immunoglobulin M (IgM) levels was the most common finding (23%). Elevated IgG levels were recorded in 2%.

The most common cellular deficiencies are absent or delayed skin-hypersensitivity reactions to tetanus and candidal antigens, depressed lymphocyte responses to mitogens, and reduced numbers of CD4+ (helper) T lymphocytes. Lymphopenia is typically present. In one study, lymphopenia affected 71% of patients with AT, with decreased B cells in 75%, CD4 T lymphocytes in 69% and CD8 T lymphocytes in 51%. The lymphocytic response to mitogens, such as phytohemagglutinin (PHA), may be in reference range or decreased. Natural killer (NK)–cell activity is in the reference range.

Despite laboratory evidence of significant immune abnormalities, opportunistic infections are uncommon. More sophisticated immune studies show normal-to-increased levels of cytokine production in both Th1 (interleukin [IL]-2, interferon [IFN]-gamma) and Th2 (IL-10, IL-4) cells.[12]

A laboratory finding unique to AT is an elevated serum alpha-fetoprotein protein (AFP) level. The karyotype reveals little or no evidence of hepatic fibrosis or hepatitis to explain the elevated AFP levels.

With the aid of molecular testing, AT can be distinguished from other autosomal recessive cerebellar ataxias, such as Friedrich ataxia, Mre11 deficiency (AT-like disease), and the oculomotor apraxias 1 (aprataxin deficiency) and 2 (senataxin deficiency). In addition, NBS1 deficiency defines Nijmegen breakage syndrome (NBS), and helicase gene defect defines Bloom syndrome.

Studies of the immune function in patients with chronic mucocutaneous candidiasis (CMC) demonstrated considerable heterogeneity, with as many as 7 groups of cellular immune responses. All patients had a defective response to candidal antigen. In some patients, defective B-cell function was also documented.

Patients with CMC do not have a delayed hypersensitivity reaction to candidal species. Patients had a normal response to other antigens, or they were anergic. In vitro tests confirmed the inability of patients' lymphocytes to proliferate or to produce certain cytokines in response to candidal antigens.

Some patients are clinically identical to other patients with CMC except that they have normal lymphocyte responses to candidal species in terms of proliferation or cytokine production. However, these same patients (with chronic localized candidiasis) do not have a delayed hypersensitivity reaction to candidal species.

Some patients have depressed levels of the IgG2 and IgG4 subclasses yet normal absolute values of IgG, IgA, and IgM. These patients appear to be unable to mount a good response to polysaccharide antigens. Hypogammaglobulinemia was reported in several other patients.

Immunoregulatory abnormalities were observed in studies of lymphocytes in vitro. Abnormal patterns of cytokine production in response to stimulation with Candida species were noted. Decreased production of some but not all type 1 cytokines (eg, IL-2 and IFN-gamma) and increased levels of IL-10 were specifically observed.

Decreased levels of NK cells were documented in 55% of 51 patients in 1 series and in 18 of 23 cases in another series. Impaired NK-cell activity against K562 target cells was seen in half of the patients described in one paper.

Whether B-cell abnormalities contribute to increased susceptibility to bacterial infections is uncertain. Deficient chemotactic activity of both neutrophils and monocytes has been described, as has abnormal antigen presentation by monocytes.

Autoantibodies against type I IFNs have been proposed as an additional diagnostic criterion for autoimmune polyglandular syndrome type I (APS I).[13]


Imaging Studies

MRI is the preferred method for radiologic evaluation in patients with AT; however, exaggerated radiographic changes are not usually visible until age 10 years. Imaging may then show ventricular dilation with diffuse cerebral atrophy. Cerebellar atrophy is marked. This finding is correlated with pathologic results showing a loss of Purkinje and granular cell layers in the cerebellum. Normal numbers of Purkinje cells at birth apparently undergo progressive degeneration.

Efforts to correlate the degree of cerebellar atrophy and the patient's ability to walk have not yielded conclusive results. This lack may be because, though the cerebellum is almost universally affected, other structures, such as anterior horn cells, dorsal columns, and peripheral nerves, may be affected to different degrees.


Other Tests

Electromyograms of patients with AT show potentials indicating disease of the anterior horn cell and correlating pathologic findings of anterior horn cell degeneration and posterior column demyelination.

Personnel in cytogenetics laboratories perform chromosomal instability tests to confirm AT and NBS to assess spontaneous and induced breakage. Chromosomal karyotyping should reveal reciprocal translocations between chromosomes 7 and 14 in AT. Absence or dysfunction of the ATM protein and mutations in the ATM gene are diagnostic findings.

Gammopathies observed in patients with AT are detected by means of immunoelectrophoresis, but they should be suspected when quantitative levels of immunoglobulin, usually IgM, are isolated.

Measurements of autoantibodies are important in patients with CMC so that the various types of CMC can be classified. Of importance, CMC can be the initial manifestation of APECED in 93% of patients. Subsequent hypoparathyroidism or adrenal insufficiency occur in these patients; mean ages of onset are 9.2 or 13.6 years, respectively.

In particularly, antibodies against interferon appear to be especially common in APS I and CMC.[14, 13]


Histologic Findings

In patients with AT, the thymus is poorly developed, with few thymocytes, absent Hassall corpuscles, and little corticomedullary demarcation.



The lifetime cancer risk for patients with AT is 10-38%. Non-Hodgkin and Hodgkin lymphomas are staged by using conventional guidelines.

Contributor Information and Disclosures

Terry W Chin, MD, PhD Associate Clinical Professor, Department of Pediatrics, University of California, Irvine, School of Medicine; Associate Director, Cystic Fibrosis Center, Attending Staff Physician, Department of Pediatric Pulmonology, Allergy, and Immunology, Memorial Miller Children's Hospital

Terry W Chin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American College of Chest Physicians, American Federation for Clinical Research, American Thoracic Society, California Society of Allergy, Asthma and Immunology, California Thoracic Society, Clinical Immunology Society, Los Angeles Pediatric Society, Western Society for Pediatric Research

Disclosure: Nothing to disclose.


Noufa Alonazi, MD, MBBS Allergy and Immunology Postdoctoral Fellow, Department of Pediatrics, Loma Linda University and Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD Faculty, Division of Allergy/Immunology and Infectious Diseases, Department of Pediatrics, Saint Peter's University Hospital

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Pediatric Research, Society for Mucosal Immunology

Disclosure: Nothing to disclose.


John Wilson Georgitis, MD Consulting Staff, Lafayette Allergy Services

John Wilson Georgitis, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American College of Chest Physicians, American Lung Association, American Medical Writers Association, and American Thoracic Society

Disclosure: Nothing to disclose.

  1. Somech R, Lev A, Grisaru-Soen G, Shiran SI, Simon AJ, Grunebaum E. Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency. Immunol Res. 2013 May. 56(1):150-4. [Medline].

  2. Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol. 2008 May. 28 Suppl 1:S11-9. [Medline].

  3. Stiehm ER. Immunologic Disorders in Infants and Children. 4th ed. WB Saunders Co; 1996.

  4. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014 Aug 20. 312(7):729-38. [Medline].

  5. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006 Aug. 91(8):2843-50. [Medline].

  6. Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998 Jul. 102(1 Pt 1):98-100. [Medline].

  7. Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol. 2008 Feb. 46(1):85-91. [Medline].

  8. LeBoeuf N, Garg A, Worobec S. The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Pediatr Dermatol. 2007 Sep-Oct. 24(5):529-33. [Medline].

  9. Hong M, Ryan KR, Arkwright PD, et al. Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Clin Exp Immunol. 2009 Apr. 156(1):40-51. [Medline]. [Full Text].

  10. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol. 2008 Nov. 128(11):2640-5. [Medline].

  11. Stray-Pedersen A, Aaberge IS, Fruh A, Abrahamsen TG. Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol. 2005 Jun. 140(3):507-16. [Medline].

  12. Pashankar F, Singhal V, Akabogu I, Gatti RA, Goldman FD. Intact T cell responses in ataxia telangiectasia. Clin Immunol. 2006 Aug. 120(2):156-62. [Medline].

  13. Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008 Nov. 93(11):4389-97. [Medline].

  14. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006 Jul. 3(7):e289. [Medline].

  15. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31. 371(5):434-46. [Medline].

  16. Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol. 2003 Feb. 90(2):259-64. [Medline].

  17. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug Information Handbook 2008-2009. 16th edition. Cleveland, Ohio: Lexi-Comp Inc; 2008.

  18. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. 2008 Nov. 28(4):765-78, viii. [Medline].

  19. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005 Aug 15. 62(16 Suppl 3):S5-11. [Medline].

  20. Siegel J. The Product: All intravenous immunoglobulins are not equivalent. Pharmacother. 2005. 25(11 Pt 2):78S-84S.

  21. Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. 1998 Jun. 101(6 Pt 1):848-9. [Medline].

  22. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006 Aug. 38(8):873-5. [Medline].

  23. Buoni S, Zannolli R, Sorrentino L, Fois A. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol. 2006 Oct. 63(10):1479-82. [Medline].

  24. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006 Jul. 91(7):610-1. [Medline].

  25. Baumgart KW, Britton WJ, Kemp A, French M, Roberton D. The spectrum of primary immunodeficiency disorders in Australia. J Allergy Clin Immunol. 1997 Sep. 100(3):415-23. [Medline].

  26. Claret Teruel G, Giner Munoz MT, Plaza Martin AM, et al. Variability of immunodeficiency associated with ataxia telangiectasia and clinical evolution in 12 affected patients. Pediatr Allergy Immunol. 2005 Nov. 16(7):615-8. [Medline].

  27. Hughes WT. Prevention of infections in patients with T cell defects. Clin Infect Dis. 1993 Nov. 17 Suppl 2:S368-71. [Medline].

  28. Mila J, Matamoros N, Pons de Ves J, Raga S, Iglesias Alzueta J. [The Spanish Registry of Primary Immunodeficiencies. REDIP-1998]. Sangre (Barc). 1999 Apr. 44(2):163-7. [Medline].

  29. Regueiro JR, Porras O, Lavin M. Ataxia-telangiectasia: a primary immunodeficiency revisted. Immunol Allergy Clin North Am. 2000. 20:177-206.

  30. Ruan QG, She JX. Autoimmune polyglandular syndrome type 1 and the autoimmune regulator. Clin Lab Med. 2004 Mar. 24(1):305-17. [Medline].

  31. Sadighi Akha AA, Humphrey RL, Winkelstein JA, Loeb DM, Lederman HM. Oligo-/monoclonal gammopathy and hypergammaglobulinemia in ataxia-telangiectasia. A study of 90 patients. Medicine (Baltimore). 1999 Nov. 78(6):370-81. [Medline].

  32. Sahama I. Radiological Imaging in Ataxia Telangiectasia: a Review. Cerebellum. 2014.

  33. Schroeder SA, Swift M, Sandoval C, Langston C. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2005 Jun. 39(6):537-43. [Medline].

  34. Schwartz SA. Intravenous immunoglobulin treatment of immunodeficiency disorders. Pediatr Clin North Am. 2000 Dec. 47(6):1355-69. [Medline].

  35. Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol. 2005 Oct. 58(10):1009-15. [Medline].

  36. Thampakkul S, Ballow M. Replacement intravenous immunoglobulin. Serum globulin therapy in patients with antibody immune deficiency. Immunol Aller Clin North Am. 2001. 21:165.

Radiograph shows an 8-month-old boy who required ventilatory support for bilateral pneumonia and who received intravenous antibiotics. The patient recovered and returned home.
Chest radiograph in an 8-month-old boy 2 weeks after he was treated for bilateral pneumonia. The patient returned to the emergency department with a fever and breathing problems.
Chest radiograph in a 9-month-old boy. The patient developed breathing problems 1 month after recovering from a second hospitalization for pneumonia. By this time, serum immunoglobulin levels from the second hospitalization were in the patient's record and showed an immunoglobulin G level of 156 mg/dL and undetectable immunoglobulin A and immunoglobulin M levels. Subsequent bronchoscopy showed the presence of Pneumocystis carinii and cytomegalovirus.
Telangiectasia of conjunctivae.
A 5-year-old boy with thrush.
Table. Intravenous Immunoglobulin Therapy [17, 18, 19, 20]
Brand(Manufacturer) Manufacturing Process pH Additives (IVIG products containing sucrose are more often associated with renal dysfunction, acute renal failure, and osmotic nephrosis, particularly with preexisting risk factors [eg, history of renal insufficiency, diabetes mellitus, age >65 y, dehydration, sepsis, paraproteinemia, nephrotoxic drugs].) Parenteral Form and Final Concentrations IgA Content mcg/mL
Carimune NF

(ZLB Behring)

Kistler-Nitschmann fractionation, pH 4, nanofiltration 6.4-6.8 6% solution: 10% sucrose, < 20 mg NaCl/g protein Lyophilized powder 3%, 6%, 9%, 12% Trace

(Grifols USA)

Cohn-Oncley fractionation, PEG precipitation, ion-exchange chromatography, pasteurization 5.1-6 Sucrose free, contains 5% D-sorbitol Liquid 5% < 50
Gammagard Liquid 10%

(Baxter Bioscience)

Cohn-Oncley cold ethanol fractionation, cation and anion exchange chromatography, solvent detergent treated, nanofiltration, low pH incubation 4.6-5.1 0.25 M glycine Ready-for-use liquid 10% 37
Gammar-P IV

(ZLB Behring)

Cohn-Oncley fraction II/III, ultrafiltration, pasteurization 6.4-7.2 5% solution: 5% sucrose, 3% albumin, 0.5% NaCl Lyophilized powder 5% < 20

(Talecris Biotherapeutics)

Cohn-Oncley fractionation, caprylate-chromatography purification, cloth and depth filtration, low pH incubation 4-4.5 Contains no sugar, contains glycine Liquid 10% 46

(Bio Products)

Solvent/detergent treatment targeted to enveloped viruses; virus filtration using Pall Ultipor to remove small viruses including nonenveloped viruses; low pH incubation 4.8-5.1 Contains sorbitol (40 mg/mL); do not administer if fructose intolerant Ready-for-use solution 5% < 10
Iveegam EN

(Baxter Bioscience)

Cohn-Oncley fraction II/III, ultrafiltration, pasteurization 6.4-7.2 5% solution: 5% glucose, 0.3% NaCl Lyophilized powder 5% < 10
Polygam S/D

Gammagard S/D

(Baxter Bioscience for the American Red Cross)

Cohn-Oncley cold ethanol fractionation, followed by ultra centrafiltration and ion exchange chromatography, solvent detergent treated 6.4-7.2 5% solution: 0.3% albumin, 2.25% glycine, 2% glucose Lyophilized powder 5%, 10% < 1.6 (5% solution)

(Octapharma USA)

9/24/10: Withdrawn from market because of unexplained reports of thromboembolic events

Cohn-Oncley fraction II/III, ultrafiltration, low pH incubation, S/D treatment pasteurization 5.1-6 10% maltose Liquid 5% 200

(Swiss Red Cross for the American Red Cross)

Kistler-Nitschmann fractionation, pH 4, trace pepsin, nanofiltration 6.6 Per gram of IgG: 1.67 g sucrose, < 20 mg NaCl Lyophilized powder 3%, 6%, 9%, 12% 720
Medscape Consult
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.